Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial

实施以提供者为中心的干预措施，以最大限度地提高在儿科肿瘤实践中接受后续护理的年轻癌症幸存者的 HPV 疫苗接种：整群随机试验

• 批准号: 10905151
• 负责人: James Klosky
• 金额: $ 58.16万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-18 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10905151
• 关键词: 17 year old; Address; Area; Cancer Survivor; Caring; Clinic; Clinical; Cluster randomized trial; Evidence based intervention; General Population; Health Personnel; Human Papilloma Virus Vaccine; Human Papilloma Virus-Related Malignant Neoplasm; Human Papillomavirus; Intervention; Knowledge; Malignant Neoplasms; Malignant neoplasm of anus; Malignant neoplasm of cervix uteri; National Cancer Institute; Outcome; Parents; Pediatric Oncology; Persons; Prevention; Provider; Recommendation; Research; Research Priority; Testing; Vaccines; childhood cancer survivor; chronic infection; effectiveness evaluation; follow-up; health care delivery; high risk; improved; prevent; skills; uptake; vaccine acceptance; young cancer survivor

Modified Project Summary/Abstract Section PROJECT SUMMARY/ABSTRACT Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). An effective vaccine exists that can prevent these cancers, but uptake of the HPV vaccine is low among young cancer survivors (fewer than 1 in 4 have received the vaccine). Lack of a healthcare provider recommendation for the HPV vaccine is the most common reason that cancer survivors fail to get the HPV vaccine. Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on improving healthcare provider knowledge about the HPV vaccine, enhancing the skills that healthcare providers need to effectively recommend the vaccine to young people and their parents, and reducing barriers to receiving the vaccine. This proposed research will evaluate the effectiveness and implementation of an evidence-based intervention, adapted for use by healthcare providers in pediatric oncology clinics, to increase the uptake of HPV vaccine among young cancer survivors (9 to 17 years of age and at least one year off-therapy). If the intervention is effective in improving and sustaining increased uptake of the HPV vaccine in young cancer survivors, this study will contribute important information needed to move forward with testing the widespread use of the intervention in pediatric oncology practices. This proposed research addresses improving healthcare delivery and clinical outcomes for cancer survivors through prevention of HPV-associated cancers, which are high-priority research areas for the National Cancer Institute.

修改后的项目摘要/摘要部分 项目概要/摘要 儿童癌症幸存者患新癌症（例如宫颈癌和肛门癌）的风险很高 由人乳头瘤病毒（HPV）持续感染引起。存在一种可以预防的有效疫苗 这些癌症，但年轻癌症幸存者中 HPV 疫苗的接种率较低（不到四分之一的人接种过 HPV 疫苗） 已接种疫苗）。最常见的情况是缺乏医疗保健提供者对 HPV 疫苗的推荐 癌症幸存者未能接种 HPV 疫苗的原因。增加 HPV 最成功的策略 普通人群的疫苗接种重点是提高医疗保健提供者对 HPV 的了解 疫苗，提高医疗保健提供者向年轻人有效推荐疫苗所需的技能 人民及其父母，并减少接受疫苗的障碍。这项拟议的研究将评估 适合医疗保健提供者使用的循证干预措施的有效性和实施 在儿科肿瘤诊所，提高年轻癌症幸存者（9 至 17 岁）对 HPV 疫苗的接种率 年龄且至少停止治疗一年）。如果干预措施能够有效改善和维持增加的 年轻癌症幸存者对 HPV 疫苗的吸收情况，这项研究将提供所需的重要信息 继续测试干预措施在儿科肿瘤学实践中的广泛使用。这个提议 研究旨在通过预防改善癌症幸存者的医疗保健服务和临床结果 HPV 相关癌症，这是国家癌症研究所的高度优先研究领域。